Molecular Imaging of σ1 Receptors In Vivo: Current Status and Perspectives

Author(s): P. Brust, W. Deuther-Conrad, K. Lehmkuhl, H. Jia, B. Wünsch

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 1 , 2014

Become EABM
Become Reviewer
Call for Editor


It is widely accepted that sigma ( σ) receptors represent a new and different avenue in the possible pharmacological treatment of cancer and several brain-related disorders. Of the two different σ receptor types the σ1 receptors are assumed to be of major impact for brain diseases. Molecular imaging of brain σ1 receptors with positron emission tomography (PET) or single photon emission computed tomography (SPECT) may provide a significant contribution to the understanding of the cross-talk between σ1 receptors and inter- and intracellular signalling systems. New insights into these functional interrelationships will allow a better diagnosis of brain and cancerous diseases and direct a rational development of new therapeutic concepts.

Keywords: Brain, chaperone, cancer, disease, fluspidine, molecular imaging, positron emission tomography, sigma receptor, signalling, single photon emission computed tomography, therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 28 November, 2013
Page: [35 - 69]
Pages: 35
DOI: 10.2174/09298673113209990214

Article Metrics

PDF: 68